Table 1.

Baseline characteristics of included trials

Author	Patient enrolled	Phase	Treatment regimes	Median age, years	Median PFS, months	No for analysis
Audeh et al, 201027	57	II	Olaparib 400 mg bid	54	NR	57
Gelmon et al, 201126	65	II	Olaparib 400 mg bid	58	7.1	65
Kaye et al, 201225	97	II	Olaparib 200 mg bid	58.5	6.5	64
			Pegylated liposomal doxorubicin	53	7.1	33
Ledermann et al, 201224	265	II	Olaparib 400 mg bid po	58	8.4	136
			Placebo	59	4.8	128
Liu et al, 201431	90	II	Olaparib 400 mg bid po	57.8	9	46
Coleman et al, 201530	50	II	Veliparib 400 mg bid po	57	8.18	50
Bell-McGuinn et al, 201629	12	II	Iniparib 8 mg/kg	NR	NR	12
Domchek et al, 201628	154	II	Olaparib 400 mg bid po	58	NR	154
Mirza et al, 201621	553	III	Niraparib 300 mg qd po	57	21	367
			Placebo	58	5.5	179
Pujade-Lauraine et al, 201723	295	III	Olaparib 150 mg bid po	56	19.1	195
			Placebo	56	5.5	99
Swisher et al, 201732	206	II	Rucaparib 600 mg bid po	NR	NR	206
Coleman et al, 201722	564	III	Rucaparib 600 mg bid po	61	16.6	375
			Placebo	62	5.4	189

Abbreviations: NR, not reported; PFS, progression-free survival; Bid, bis in die; Po, per os.